The stock of ESSA Pharma Inc (TSE:EPI) is a huge mover today! About 24,820 shares traded hands or 225.47% up from the average. ESSA Pharma Inc (TSE:EPI) has declined 17.72% since April 26, 2016 and is downtrending. It has underperformed by 23.74% the S&P500.
The move comes after 9 months positive chart setup for the $114.49 million company. It was reported on Nov, 28 by Barchart.com. We have $3.61 PT which if reached, will make TSE:EPI worth $3.43 million more.
More notable recent ESSA Pharma Inc (TSE:EPI) news were published by: Prnewswire.com which released: “ESSA Pharma Inc. Receives FDA Approval to Commence Clinical Development” on September 23, 2015, also Prnewswire.com with their article: “ESSA Pharma Inc. Receives FDA Response on IND Application” published on May 04, 2015, Prnewswire.com published: “ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for …” on March 31, 2015. More interesting news about ESSA Pharma Inc (TSE:EPI) were released by: Prnewswire.com and their article: “ESSA Pharma Announces Closing of US$15 Million Private Placement” published on January 14, 2016 as well as Seekingalpha.com‘s news article titled: “ESSA Pharma nabs $10M capital raise; shares down 11%” with publication date: February 01, 2001.
ESSA Pharma, Inc. is a Canada-based clinical-stage pharmaceutical company. The company has a market cap of $114.49 million. The Firm is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). It currently has negative earnings. The Company’s segment is the development of small molecule drugs for prostate cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.